Long-term outcomes for risk groups in the validation cohort defined by 2 biomarker algorithms. We identified high-risk (HR; red) and low-risk (LR; blue) groups for patients in the validation cohort (n = 378) using optimal thresholds that we defined in the training cohort: (A) TNFR1 + TIM3, (B) ST2 + REG3α, (C) TNFR1 + ST2, and (D) TNFR1 + REG3α. Left panel: the proportion of steroid-treated patients with a CR or PR at day 28. Middle panel: cumulative incidence of 6-month NRM. Right panel: overall survival in the first 6 months.